- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Patent holdings for IPC class A61P 1/16
Total number of patents in this class: 7810
10-year publication summary
|
171
|
212
|
414
|
523
|
587
|
686
|
756
|
726
|
633
|
438
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10741 |
60 |
| Genfit | 271 |
58 |
| Daiichi Sankyo Company, Limited | 1878 |
53 |
| Gilead Sciences, Inc. | 2035 |
52 |
| Osaka University | 3384 |
50 |
| Albireo AB | 170 |
49 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
48 |
| Eli Lilly and Company | 3855 |
47 |
| The Regents of the University of California | 19989 |
42 |
| Takeda Pharmaceutical Company Limited | 2711 |
40 |
| Bristol-myers Squibb Company | 4881 |
38 |
| Pfizer Inc. | 3368 |
35 |
| Chugai Seiyaku Kabushiki Kaisha | 1362 |
33 |
| Viking Therapeutics, Inc. | 53 |
32 |
| InterCept Pharmaceuticals, Inc. | 206 |
31 |
| AstraZeneca AB | 2897 |
29 |
| Boehringer Ingelheim International GmbH | 4641 |
29 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3362 |
29 |
| Kowa Company, Ltd. | 1198 |
29 |
| Regeneron Pharmaceuticals, Inc. | 4296 |
28 |
| Other owners | 6998 |